Moleculin Biotech, Inc.

5300 Memorial Drive, Suite 950

Houston, TX 77007

 

 

February 24, 2025

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

 

 

Re:

Moleculin Biotech, Inc.

Registration Statement on Form S-1

Registration No. 333-283820 (“Registration Statement”)

 

Ladies and Gentlemen:

 

Please be advised that the Company hereby requests withdrawal of the above-referenced Registration Statement pursuant to Rules 477 and 478 of Regulation C promulgated by the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”). The Registration Statement was originally filed on December 13, 2024 and has not been declared effective. The Company has determined not to proceed with the planned offering and confirms that no securities were sold in connection with the offering. Accordingly, the Company hereby requests withdrawal of the Registration Statement as of the date hereof or at the earliest practicable date hereafter.

 

The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.

 

  Very truly yours,  
     
  Moleculin Biotech, Inc.  

 

 

 

 

 

 

 

 

 

 

 

 

By:

/s/ Jonathan P. Foster

 

 

 

  Name: Jonathan P. Foster

 

 

 

  Title: Chief Financial Officer

 

 

 

 
Grafico Azioni Moleculin Biotech (NASDAQ:MBRX)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Moleculin Biotech
Grafico Azioni Moleculin Biotech (NASDAQ:MBRX)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Moleculin Biotech